Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

IntroductionMatching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. Unlike traditional single marker tests, comprehensive genomic profiling (CG...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Zachary D. Wallen, Mary K. Nesline, Marni Tierno, Alison Roos, Erica Schnettler, Hatim Husain, Pratheesh Sathyan, Brian Caveney, Marcia Eisenberg, Eric A. Severson, Shakti H. Ramkissoon
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Subjects:	non-small cell lung cancer genomic profiling immune checkpoint inhibitors TMB PD-L1 clinical utility
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1473327/full